Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 4, 2003, Pages 987-995

  Goodwin, Amy K ^a,b   Pynnonen, Dori M ^a   Baker, Lisa E ^a  

^a WESTERN MICHIGAN UNIVERSITY   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

D Amphetamine; Drug discrimination; Fenfluramine; Haloperidol; LSD; MDL 100,907; MDMA; Rats

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPHETAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FENFLURAMINE; HALOPERIDOL; LYSERGIDE; SEROTONIN; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG DISCRIMINATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; STIMULATION;

EID: 0037346943     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00029-7     Document Type: Article

References (42)

1. Baker L.E., Taylor M.M. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Pharmacol. Biochem. Behav. 57:1997;737-748.
2. Baker L.E., Broadbent E.K., Michael E.K., Matthews P.K., Metosh C.A., Saunders R.B.et al. Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav. Pharmacol. 6:1995;263-275.
3. Baker L.E., Virden T.B., Miller M.E., Sullivan C.L. A time course analysis of the discriminative stimulus effects of the optical isomers of 3,4-methylenedioxymethamphetamine (MDMA). Pharmacol. Biochem. Behav. 58:1997;505-516.
4. Beck C. MDMA - Die fruhen Jahre. 1997;European College for the Study of Consciousness, Bad Boll, Germany.
5. Callahan P.M., Appel J.B. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. J. Pharmacol. Exp. Ther. 246(3):1988;866-870.
6. Cameron O.G., Appel J.B. A behavioral and pharmacological analysis of some discriminable properties of D-LSD in rats. Psychopharmacologia. 33:1973;117-134.
7. Cami J., Farre M., Mas M. Human pharmacology of 3,4-methylenedioxymethamphetamine ("Ecstasy"): psychomotor performance and subjective effects. J. Clin. Psychopharmacol. 20:2000;455-466.
8. Eisner B. Ecstasy: the MDMA story. 1989;Ronin Press, Berkeley (CA).
9. Evans S.M., Johanson C.E. Discriminative stimulus properties of (±)-3,4-methylenedioxymethamphetamine and (±)-3,4-methylenedioxyamphetamine in pigeons. Drug Alcohol. Depend. 18:1986;159-164.
10. Evans S.M., Zacny J.P., Johanson C.W. Three-choice discrimination among (+)-amphetamine, fenfluramine, and saline in pigeons. Pharmacol. Biochem. Behav. 35:1990;971-980.
11. Extance K., Goudie A.J. Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacology. 73:1981;363-371.
12. Glennon R.A., Misenheimer B.R. Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline. Pharmacol. Biochem. Behav. 33:1989;909-912.
13. Glennon R.A., Young R. Further investigation of the discriminative stimulus properties of MDA. Pharmacol. Biochem. Behav. 20:1984;501-505.
14. Glennon R.A., Rosecrans J.A., Young R. The use of the drug discrimination paradigm for studying hallucinogenic agents: a review. Colpaert F.C., Slangen J.L. Drug discrimination: applications in CNS pharmacology. 1982;69-98 Elsevier Biomedical Press, Amsterdam.
15. 3 antagonists. Pharmacol. Biochem. Behav. 43:1992;1099-1106.
16. Goodwin A.K., Baker L.E. A three-choice discrimination procedure dissociates the discriminative stimulus effects of D-amphetamine and MDMA in rats. Exp. Clin. Psychopharmacol. 8(3):2002;415-423.
17. Goodwin A.K., Baker L.E. An analysis of the utility of differential outcome procedures in drug discrimination research. Behav. Pharmacol. 13:2002;1-9.
18. Goudie A.J. Discriminative stimulus properties of amphetamine, cathinone, and related agents. Glennon R.A., Jarbe R., Frankenheim J. Drug discrimination: applications to drug abuse research (NIDA Research Monograph No. 116). 1991;45-60 U.S. Government Printing Office, Rockville (MD).
19. Grant K.A. Strategies for understanding the pharmacological effects of ethanol with drug discrimination procedures. Pharmacol. Biochem. Behav. 64(2):1999;261-267.
20. Greer G., Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J. Psychoactive Drugs. 18(4):1986;319-327.
21. Grinspoon L., Bakalar J.B. Can drugs be used to enhance the psychotherapeutic process? Am. J. Psychother. 40:1986;393-404.
22. Ho B.T., Huang J.T. Role of dopamine in D-amphetamine-induced discriminative responding. Pharmacol. Biochem. Behav. 3:1975;1085-1092.
23. Holland J. The history of MDMA. Holland J. Ecstasy: the complete guide. 2001;11-20 Park Street Press, Rochester (VT).
24. Malberg J.E., Bonson K.R. How MDMA works in the brain. Holland J. Ecstasy: the complete guide. 2001;29-38 Park Street Press, Rochester (VT).
25. McDowell D.M., Kleber H.G. MDMA: its history and pharmacology. Psychiatr. Ann. 24:1994;127-130.
26. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoactive Drugs. 18:1986;305-318.
27. Nielsen E., Jepsen S. Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur. J. Pharmacol. 11:1985;167-176.
28. Oberlander R., Nichols D.E. Drug discrimination studies with MDMA and amphetamine. Psychopharmacology. 95:1988;71-76.
29. Pentney A.R. An exploration of the history and controversies surrounding MDMA and MDA. J. Psychoactive Drugs. 33(3):2001;213-220.
30. Peroutka S.J., Newman H., Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology. 1:1988;273-277.
31. Ray O., Ksir C. Drugs, society, and human behavior. 1999;WCB McGraw-Hill, Boston (MA).
32. Sadzot B., Baraban J.M., Glennon R.A., Lyon R.A., Leonhardt S., Jan C.R.et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology. 98:1989;495-499.
33. Schechter M.D. Discriminative profile of MDMA. Pharmacol. Biochem. Behav. 24:1986;1533-1537.
34. Schechter M.D. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol. Biochem. Behav. 31:1989;817-824.
35. Schechter M.D. MDMA-like stimulus effects of hallucinogens in male-fawn-hooded rats. Pharmacol. Biochem. Behav. 59(2):1998;265-270.
36. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analog, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 223:1992;65-74.
37. Shulgin A., Nichols D.E. Characterization of three new psychotomimetics. Stillman R.C., Willette R.W. The psychopharmacology of hallucinogens. 1978;Pergamon, New York.
38. Siegal R.K. MDMA: nonmedical use and intoxication. J. Psychoactive Drugs. 18:1986;349-354.
39. Solowij N., Hall W., Nicole L. Recreational MDMA use in Sydney: a profile of "Ecstasy" users and their experiences with the drug. Br. J. Addict. 87:1992;1161-1172.
40. Stolerman I.P. Drug discrimination. Van Haaren F. Methods in behavioral pharmacology. 1993;217-224 Elsevier Science, Amsterdam.
41. Woolverton W.L. Pharmacological analysis of the discriminative stimulus effects of D-amphetamine in rhesus monkeys. Pharmacologist. 26:1984;161.
42. Yokel R., Wise R. Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology. 48:1976;311-318.